期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 896, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ejphar.2021.173922
关键词
SARS-CoV-2; Homology modelling; Molecular docking; Repurposing; TMPRSS2; ACE2
资金
- Manipal Academy of Higher Education, Manipal, Karnataka India
- ICMR, New Delhi [45/33/2019/PHA/BMS]
- DST-SERB, New Delhi, India [EMR/2016/007006]
This study explores drug repurposing for COVID-19 by targeting TMPRSS2 and ACE2, identifying potential entry inhibitors. Among the FDA-approved drugs screened, lopinavir and valrubicin show superior dual inhibition properties, with the potential to prevent SARS-CoV-2 entry into host cells. Further in vitro and in vivo studies are needed for clinical exploration of these drugs.
The coronavirus disease (COVID-19) is spreading between human populations mainly through nasal droplets. Currently, the vaccines have great hope, but it takes years for testing its efficacy in human. As there is no specific drug treatment available for COVID-19 pandemic, we explored in silico repurposing of drugs with dual inhibition properties by targeting transmembrane serine protease 2 (TMPRSS2) and human angiotensin-converting enzyme 2 (ACE2) from FDA-approved drugs. The TMPRSS2 and ACE2 dual inhibitors in COVID-19 would be a novel antiviral class of drugs called entry inhibitors. For this purpose, approximately 2800 US-FDA approved drugs were docked using a virtual docking tool with the targets TMPRSS2 and ACE2. The best-fit drugs were selected as per docking scores and visual outcomes. Later on, drugs were selected on the basis of molecular dynamics simulations. The drugs alvimopan, arbekacin, dequalinum, fleroxacin, lopinavir, and valrubicin were shortlisted by visual analysis and molecular dynamics simulations. Among these, lopinavir and valrubicin were found to be superior in terms of dual inhibition. Thus, lopinavir and valrubicin have the potential of dual-target inhibition whereby preventing SARS-CoV-2 entry to the host. For repurposing of these drugs, further screening in vitro and in vivo would help in exploring clinically.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据